Jump to content
This site uses cookies. Continued use is acceptance of our Terms of Use and Privacy Policy. More Info... ×
  • Welcome to Celiac.com!

    You have found your celiac tribe! Join us and ask questions in our forum, share your story, and connect with others.




  • Celiac.com Sponsor (A1):



    Celiac.com Sponsor (A1-M):


  • Get Celiac.com Updates:
    Support Our Content
    eNewsletter
    Donate
  • Jefferson Adams
    Jefferson Adams

    FDA Issues New Guidelines for Celiac Drug Trials

    Reviewed and edited by a celiac disease expert.

    The FDA has issued new guidelines for celiac drug trials. Here's what they say.

    FDA Issues New Guidelines for Celiac Drug Trials - Great spangled fritillary. Image: CC BY-SA 2.0--Thomas Berg
    Caption: Great spangled fritillary. Image: CC BY-SA 2.0--Thomas Berg

    Celiac.com 07/04/2022 - The Food and Drug Administration (FDA) has issued a set of new guidelines for companies doing celiac disease drug trials. The agency noted that the guidance is intended only to provide clarity regarding existing requirements, and should be viewed solely as recommendations, unless they mention specific regulations or laws.

    The FDA directs sponsors of trials for clinical drugs to ensure the following regarding celiac disease patients on a gluten-free diet:

    Trial population

    Celiac.com Sponsor (A12):
    Patients should undergo diagnostic esophagogastroduodenoscopy, with multiple biopsies to confirm celiac diagnosis. The biopsies should include one or two samples of the duodenal bulb and at least four samples of the distal duodenum.

    To avoid inclusion of patients whose symptoms are not celiac-related, patients should receive esophagogastroduodenoscopy screening with biopsy to ensure they meet histologic eligibility criteria at the time of trial enrollment.

    Patients should be symptomatic at baseline, based on enrollment criteria, to allow for evaluation of symptom improvement.

    Prior to trail enrollment and for the full duration, patients should follow to a strict gluten-free diet with input from trained dietitians.

    Trial design

    The FDA recommends using randomized, double-blind, placebo-controlled trial design.

    Before randomization of participants, sponsors should include a screening period to confirm histologic eligibility criteria, document clinical signs and symptoms, and train patients and/or providers in collecting clinical outcome assessment data.

    Trial duration and outcome assessments should be informed by the therapy goal, expected drug onset of action and the time frame in which clinical benefit is observable.
    The FDA recommends a placebo-controlled treatment period of at least 52 weeks for drugs intended for chronic use, with continued patient adherence to a gluten-free diet.

    Efficacy assessments for both clinical and histologic endpoints may be evaluated at week 24, and esophagogastroduodenoscopy with biopsy should be performed at week 52 to assess durability of response.

    Sponsors should make sure their patients follow a gluten-free diet for the complete treatment period.

    Efficacy and clinical outcome assessments

    Trails intended to support market approval should include coprimary endpoints to assess a drug’s effect on clinical signs, symptoms and related underlying mucosal condition.

    The FDA also recommends a pre-specified secondary endpoint to determine the number of patients who see improvement of clinical signs, symptoms and mucosal inflammation.

    Trial sponsors should seek FDA input early, when critical milestones are met, and throughout drug development.

    Sponsors should also identify disease and treatment burdens using patient input. To better assess symptom severity and event-related signs and symptoms, sponsors should ask patients to rate their worst experience and frequency of a specific sign or symptom over a 24-hour period.

    Statistical and safety considerations

    To be demonstrate efficacy, trial results should demonstrate statistical significance for both clinical and histological endpoints, and analyses should include all randomized patients.

    Sponsors should assess gluten-free diet adherence, which could alter efficacy data. Moreover, sponsors should talk with patients about the importance of following a strict gluten-free diet, since the benefit of the drug is still unknown.

    To assess the safety of drugs intended for long-term use, patients should be follow the intended market dosage for at least one year.

    The FDA recommends that sponsors include safety analyses to compare risk and confidence intervals in treatment groups.
     

    Read the full recommendations at FDA.gov



    User Feedback

    Recommended Comments

    There are no comments to display.



    Create an account or sign in to comment

    You need to be a member in order to leave a comment

    Create an account

    Sign up for a new account in our community. It's easy!

    Register a new account

    Sign in

    Already have an account? Sign in here.

    Sign In Now

  • Get Celiac.com Updates:
    Support Celiac.com:
    Donate
  • About Me

    Jefferson Adams

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University. His articles, essays, poems, stories and book reviews have appeared in numerous magazines, journals, and websites, including North American Project, Antioch Review, Caliban, Mississippi Review, Slate, and more. He is the author of more than 2,500 articles on celiac disease. His university coursework includes studies in science, scientific methodology, biology, anatomy, physiology, medicine, logic, and advanced research. He previously devised health and medical content for Colgate, Dove, Pfizer, Sharecare, Walgreens, and more. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of numerous books, including "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

    >VIEW ALL ARTICLES BY JEFFERSON ADAMS

     


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-M):




  • Related Articles

    Jefferson Adams
    FDA Approves New Test for Celiac Disease
    Celiac.com 07/18/2019 - Autoimmune conditions cause the body to attack its own healthy cells. There are nearly one-hundred known autoimmune conditions, including lupus, celiac disease, and rheumatoid arthritis.
    Diagnosing autoimmune conditions can sometimes be difficult, so any progress toward faster, cheaper, or more reliable testing methods could play a significant role in improving diagnosis and reducing time to treatment. Approval by the FDA is key to making such tests available commercially.
    A New York startup company, Aesku.NY, has received FDA approval for tests to detect two of those autoimmune diseases, with tests for other diseases expected to follow. 
    The approved tests for celiac disease, and the connective tissue disorder, lupus, would still require patients ...


    Jefferson Adams
    FDA Urges Transition to Disposable Duodenoscopes
    Celiac.com 09/10/2019 - The US Food and Drug Administration (FDA) is recommending that manufacturers of duodenoscopes, along with health care facilities, switch to duodenoscopes with disposable parts to help reduce the risk of patient infection.
    Post-market surveillance studies ordered by the FDA reveal that contamination rates for reusable duodenoscopes remain unacceptably high after reprocessing, with avoidable deaths and infections still occurring.
    As a result, the agency is now recommending the elimination of duodenoscopes with fixed endcaps in favor of those with either disposable components, including disposable endcaps, or fully disposable duodenoscopes as they become available.
    By simplifying or eliminating the need for reprocessing, disposable duodenoscopes...


    Scott Adams
    FDA Relaxes Food Labeling Rules During Covid-19 Pandemic
    Celiac.com 06/15/2020 - Usually, when a food manufacturer makes an ingredient change, even a minor one, to a food product, they must produce a new label for all the changed products. However, Covid-19 has changed that. Responding to calls from food manufacturers facing supply chain problems in the wake of the Covid-19 pandemic, the Food and Drug Administration (FDA) is relaxing some labeling requirements for certain ingredients in food in the U.S.
    The move will give food manufacturers the ability make small changes to the ingredients in a product without making label changes. That may mean adding, omitting, or blending ingredients to meet the product needs.
    The FDA guidance on the matter states that such labeling changes "should not cause any adverse health effect, including...


    Scott Adams
    FDA Rules All Distilled Alcohol is Gluten-Free
    Celiac.com 08/19/2020 - The US Food and Drug Administration (FDA) has ruled that distilled foods and spirits made from gluten-containing grains can be labelled as ‘gluten-free.’ The FDA ruling covers fermented and distilled foods, or foods that contain fermented or distilled ingredients, which are made using gluten-containing grains such as rye, barley and wheat. The ruling changes the previous FDA requirement that distilled products labeled "gluten-free" must contain no gluten ingredients from start to finish.
    The change was hailed by Chris Swonger, president and CEO of the the Distilled Spirits Council of the United States (Discus), who said: “We commend FDA for this consumer-friendly ruling that will allow ‘gluten-free’ labelling claims to be included on distilled foods made from...


  • Recent Activity

    1. - trents replied to alimb's topic in Coping with Celiac Disease
      1

      How to keep water down?

    2. - alimb posted a topic in Coping with Celiac Disease
      1

      How to keep water down?

    3. - PixieSticks replied to PixieSticks's topic in Super Sensitive People
      2

      Working in a kitchen with gluten?

    4. - BoiseNic replied to BoiseNic's topic in Dermatitis Herpetiformis
      11

      Skinesa

    5. - knitty kitty replied to Whyz's topic in Celiac Disease Pre-Diagnosis, Testing & Symptoms
      6

      Feeling ill


  • Celiac.com Sponsor (A19):



  • Member Statistics

    • Total Members
      126,543
    • Most Online (within 30 mins)
      7,748

    alimb
    Newest Member
    alimb
    Joined

  • Celiac.com Sponsor (A20):


  • Forum Statistics

    • Total Topics
      120.9k
    • Total Posts
      69.5k

  • Celiac.com Sponsor (A22):





  • Celiac.com Sponsor (A21):



  • Popular Now

    • Whyz
      6
    • Art Maltman
      6
    • JA917
      13
    • Dana Gilcrease
      5
    • GardeningForHealth
  • Popular Articles

    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
  • Upcoming Events

×
×
  • Create New...